Measurement of the extracellular volume of human melanoma xenografts by contrast enhanced magnetic resonance imaging

被引:11
作者
Bjornæs, I [1 ]
Halsor, EF [1 ]
Skretting, A [1 ]
Rofstad, EK [1 ]
机构
[1] Norwegian Radium Hosp, Dept Biophys, N-0310 Oslo, Norway
关键词
extracellular volume fraction; contrast-enhanced MRI; quantitative MRI; human tumor xenograft;
D O I
10.1016/S0730-725X(99)00109-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The magnitude of the extracellular volume fraction (ECV) of tumors is of importance for the transport of macromolecular therapeutic agents from the vessel wall to the tumor cells. The aim of this study was to develop a method for measurement of tumor ECV by contrast enhanced MRI. Tumors of two human amelanotic melanoma xenograft lines (A-07 and R-18) grown intradermally in Balb/c nu/nu mice were used as model system, and muscle tissue was used as control. The renal arteries of the mice were ligated prior to i.v. administration of Gd-DTPA, and an MRI protocol for calculating Gd-DTPA concentration in tissue was followed. ECV was calculated from the Gd-DTPA concentrations in the tissue and in a plasma sample. In muscle tissue, the concentration reached a constant level after 1 min and the ECV was calculated to be 0.12 (+/- 0.01), consistent with values reported in the literature. Individual tumors showed large differences in the uptake of Gd-DTPA. The Cd-DTPA concentration in the tissue at 40 min after the Gd-DTPA administration was used to calculate tumor ECV. The ECV was found to differ significantly among regions of individual tumors and among individual tumors. The ECV ranged from 0.075 to 0.33 for A-07 tumors and from 0.016 to 0.097 for R-18 tumors. The intra- and intertumor heterogeneity in ECV was confirmed by histologic findings, showing that contrast enhanced MRI is suitable for non-invasive studies of the ECV in experimental tumors without necrosis. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:41 / 48
页数:8
相关论文
共 22 条
[1]  
BRAMMER I, 1987, RODENT TUMOR MODELS, P97
[2]  
BRAUNSCHWEIGER P G, 1986, Magnetic Resonance Imaging, V4, P335, DOI 10.1016/0730-725X(86)91043-X
[3]   DYNAMIC GD-DTPA ENHANCED MRI MEASUREMENT OF TISSUE CELL-VOLUME FRACTION [J].
DONAHUE, KM ;
WEISSKOFF, RM ;
PARMELEE, DJ ;
CALLAHAN, RJ ;
WILKINSON, RA ;
MANDEVILLE, JB ;
ROSEN, BR .
MAGNETIC RESONANCE IN MEDICINE, 1995, 34 (03) :423-432
[4]   EVALUATION OF TUMOR BLOOD PERFUSION BY DYNAMIC MRI AND CT IN PATIENTS UNDERGOING THERMORADIOTHERAPY [J].
FELDMANN, HJ ;
SIEVERS, K ;
FULLER, J ;
MOLLS, M ;
LOHR, E .
EUROPEAN JOURNAL OF RADIOLOGY, 1993, 16 (03) :224-229
[5]  
FUJII K, 1992, AM J NEURORADIOL, V13, P1215
[6]  
GULLINO PM, 1965, CANCER RES, V25, P727
[7]   FAST MR-IMAGING - TECHNIQUES AND CLINICAL-APPLICATIONS [J].
HAACKE, EM ;
TKACH, JA .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1990, 155 (05) :951-964
[8]   METHOD FELL THE QUANTITATIVE ASSESSMENT OF CONTRAST AGENT UPTAKE IN DYNAMIC CONTRAST-ENHANCED MRT [J].
HITTMAIR, K ;
GOMISCEK, G ;
LANGENBERGER, K ;
RECHT, M ;
IMHOF, H ;
KRAMER, J .
MAGNETIC RESONANCE IN MEDICINE, 1994, 31 (05) :567-571
[9]   VASCULAR AND INTERSTITIAL BARRIERS TO DELIVERY OF THERAPEUTIC AGENTS IN TUMORS [J].
JAIN, RK .
CANCER AND METASTASIS REVIEWS, 1990, 9 (03) :253-266
[10]  
JAIN RK, 1987, CANCER RES, V47, P3039